您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Kanamycin A
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Kanamycin A
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Kanamycin A图片
CAS NO:59-01-8
包装与价格:
包装价格(元)
5g电议
10g电议
25g电议

产品介绍
A broad spectrum antibiotic
Cas No.59-01-8
别名卡那霉素; 卡那霉素 A; Kanamycin A
化学名O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[6-amino-6-deoxy-α-D-glucopyranosyl-(1→4)]-2-deoxy-D-streptamine
Canonical SMILESN[C@H]([C@H]1O)[C@H](O)[C@@H](CO)O[C@]1([H])O[C@H]([C@H]2O)[C@H](N)C[C@H](N)[C@H]2OC3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O
分子式C18H36N4O11
分子量484.5
溶解度<4.8mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Kanamycin A is a broad spectrum antibiotic.

Kanamycin A was first isolated in 1957 by Hamao Umezawa from the bacterium Streptomyces kanamyceticus.

In vitro: In previous study, kanamycin A was found to block a single cycle of translocation on the poly[U]-ribosome, carrying N-acetyl-diPhe-tRNA on the acceptor site and deacylated tRNA at the donor site. The GTPase reaction, catalyzed by EF-G and ribosomes, was not significantly affected by kanamycin A. The results with kanamycin A differed from those obtained with fusidic acid, suggesting that the mechanism of translocation inhibition might be differen [1].

In vivo: Twelve male Lister hooded rats were conditioned to discriminate an 8 kHz tone and were subsequently injected subcutaneously with kanamycin A for 28 days. Results showed that only one rat was unaffected by the kanamycin A. The onset of hearing impairment generally occurred during the fourth week of kanamycin dosage although the earliest onset was towards the end of the second week. In most animals the hearing impairment progressed after kanamycin A was stopped and in one rat there was a latency between the end of drug dosage and onset of hearing impairment [2].

Clinical trial: Kanamycin A is an antibiotic used to treat severe bacterial infections and tuberculosis. It is not a first line treatment. Kanamycin A is recommended for short-term use only [3].

References:
[1] Misumi, M.  and Tanaka, N. Mechanism of inhibition of translocation by kanamycin and viomycin: A comparative study with fusidic acid. Biochemical and Biophysical Research Communications 92(2), 647-654 (1980).
[2] Harpur ES, D'Arcy PF.  The quantification of kanamycin ototoxicity in the rat using conditioned tone discrimination. J Pharm Pharmacol. 1975 Dec;27(12):907-13.
[3] https://en. wikipedia.org/wiki/Kanamycin_A